PYXS
Pyxis Oncology, Inc.NASDAQHealthcare$1.48+0.68%ClosedMarket Cap: $93.0M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
1.69
P/S
6.57
EV/EBITDA
-1.20
DCF Value
$1.88
FCF Yield
-69.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
103.1%
Operating Margin
-609.2%
Net Margin
-574.5%
ROE
-101.8%
ROA
-87.0%
ROIC
-117.1%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $11.0M | 103.9% | $-18.3M | $-18.1M | $-0.29 | — |
| FY 2025 | $13.9M | 82.8% | $-84.4M | $-79.6M | $-1.28 | — |
| Q3 2025 | $0.00 | NaN% | $-23.5M | $-22.0M | $-0.35 | — |
| Q2 2025 | $2.8M | 100.0% | $-19.8M | $-18.4M | $-0.30 | — |
| Q1 2025 | $0.00 | NaN% | $-22.9M | $-21.2M | $-0.35 | — |
| Q4 2024 | $0.00 | NaN% | $-40.1M | $-35.6M | $-0.58 | — |
| FY 2024 | $16.1M | 97.1% | $-89.5M | $-77.3M | $-1.32 | — |
| Q3 2024 | $0.00 | NaN% | $-23.8M | $-21.2M | $-0.35 | — |
| Q2 2024 | $0.00 | NaN% | $-20.0M | $-17.3M | $-0.29 | — |
| Q1 2024 | $16.1M | 97.1% | $-5.6M | $-3.3M | $-0.06 | — |
| Q4 2023 | $0.00 | NaN% | $-17.8M | $-15.6M | $-0.35 | — |
| FY 2023 | $0.00 | NaN% | $-82.2M | $-73.8M | $-1.85 | — |